Adial Pharmaceuticals Inc (ADIL) Actualités

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Adial Pharmaceuticals Announces Positive Topline Results from the AD04-103 Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

Confirmed relative bioavailability to the reference standard, dose proportional increases in pharmacokinetic...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Adial Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

GLEN ALLEN, Va., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the...

Form 8-K - Current report

Form 8-K - Current report

Adial Pharmaceuticals Appoints Vinay Shah as Chief Financial Officer

GLEN ALLEN, Va., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the...

Adial Pharmaceuticals to Present at the 2024 ThinkEquity Conference

GLEN ALLEN, Va., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the...

Adial Pharmaceuticals Receives Notice of Allowance for U.S. Patent Covering Expanded Genotype Combinations Identified Using the Company’s Genetic Diagnostic for Addiction Treatment

GLEN ALLEN, Va., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the...

Adial Pharmaceuticals Commends the National Institute on Alcohol Abuse and Alcoholism's New Definition of Recovery

GLEN ALLEN, Va., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the...

Form ARS - Annual Report to Security Holders

Form DEF 14A - Other definitive proxy statements

Adial Pharmaceuticals Announces Database Lock in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

GLEN ALLEN, Va., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or...

Adial Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference

GLEN ALLEN, Va., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or...

Adial Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update

GLEN ALLEN, Va., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the...